RxDoctor Payments DataLook up a doctor →

Jeannette Jakus, MD

Dermatology · Brooklyn, NYNPI 1477711422

Payments from drug & device makers

$1,018,737in general payments, 2019–2025

Across 626 payments — averaging $1627.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$372K
  • Regeneron$164K
  • Dermavant Sciences, Inc.$125K
  • Pfizer$121K
  • Amgen$85K
  • Galderma Laboratories, L.p.$52K
  • plus $98K from 21 others

What the payments were for

  • Consulting fees$32,80941%
  • Speaking & faculty fees$41,55052%
  • Travel & lodging$9911%
  • Food & beverage$3,8135%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,018,737 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$4,990
Medicare patients
41
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab14$181,426
Dupixent PenDupilumab22$78,800
OpzeluraRuxolitinib Phosphate16$30,218
ZoryveRoflumilast17$13,962
Tacrolimus24$3,636
Pimecrolimus11$2,573
Clobetasol Propionate43$2,497
Ketoconazole76$2,087
Triamcinolone Acetonide72$1,138
Fluocinolone Acetonide21$581
Clindamycin Phosphate14$352
Doxycycline Hyclate14$264
Hydrocortisone29$188
Mupirocin16$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$4,803$181,42614 claims
Incyte CorporationOpzelura$372,077$30,21816 claims
Arcutis Biotherapeutics, Inc.Zoryve$39,276$13,96217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →